Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis

The present study aimed to investigate the clinical characteristics and outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with osimertinib, and focused on the resistance mechanism to osimertinib in a real-world setting. Data from 128 patients with advanced NSCLC who were...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Nijia, Duan, Jingjing, Wang, Lingxiong, Dong, Zhouhuan, Liu, Zhefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399948/
https://www.ncbi.nlm.nih.gov/pubmed/32782544
http://dx.doi.org/10.3892/ol.2020.11801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399948/
https://www.ncbi.nlm.nih.gov/pubmed/32782544
http://dx.doi.org/10.3892/ol.2020.11801

Ejemplares similares